Clinical trials: Staphylococcal Aureus Infection
Pressure Ulcer
Phage Therapy for the Prevention and Treatment of Pressure Ulcers.
This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.
- Trial name
- NCT04815798
- Testing
- Bacteriophage-loaded Microcapsule Spray, Standard of Care
- Volunteers
- 69 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
Skin Infection, Bacterial Infection
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.
- Trial name
- NCT02052388
- Testing
- Daptomycin, Brilacidin
- Where
- 4 sites in United States
- Volunteers
- 215 people
- Sponsor
- Cellceutix Corporation
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthcare Associated Infection, Nosocomial Infection
Red Light Photobiomodulation and Topical Disinfectants
The goal of this clinical trial is to evaluate the potential effects of photobiomodulation when used with topical disinfectants in the anterior nares of healthy adults.
- Conditions
- Healthcare Associated Infection, Nosocomial Infection, Surgical Site Infection
- Trial name
- NCT05797818
- Testing
- Methylene Blue Only, Chlorhexidine Gluconate Only, Methylene Blue + Chlorhexidine Gluconate
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ondine Biomedical Inc.
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Infections, Soft Tissue
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
The study evaluates the safety, immunogenicity, and efficacy of the GSK S. aureus candidate vaccine (GSK3878858A) when administered to two groups: healthy adults (dose-escalation phase) and adults aged 18 to 64 years with a…
- Trial name
- NCT04420221
- Testing
- Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Staphylococcal Infection
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects.
- Trial name
- NCT00735839
- Testing
- V710
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Staphylococcal Infection
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).
- Trial name
- NCT00770341
- Testing
- Daptomycin 4 mg/kg, Comparator: vancomycin, Daptomycin 6 mg/kg
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Ventilator Associated Pneumonia, Staphylococcus Aureus
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE-2 (NCT05331885)
- Testing
- Suvratoxumab
- Where
- 27 sites in Belgium, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcal Infections
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to <86 years.
- Trial name
- NCT02492958
- Testing
- Staphylococcus aureus 4-antigen vaccine
- Where
- 2 sites in Japan
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Infections
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus…
- Trial name
- NCT01643941
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 7 sites in United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA), (Susceptible or Methicillin Resistant)
Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus
The study investigates the safety and efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).
- Trial name
- NCT01211470
- Testing
- Daptomycin, PMX-30063-investigational drug
- Where
- 8 sites in Canada, Russia and 1 more
- Volunteers
- 215 people
- Sponsor
- PolyMedix, Inc.
Staphylococcal Infections, Chronic Kidney Failure
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a…
- Trial name
- SHIELD-2 (NCT00130260)
- Testing
- Staph aureus types 5 and 8 conjugate vaccine
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Surgical Site Infections, Infections
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada
This is a Phase 4 multi-center, group-randomized, crossover trial to compare nasal antimicrobial photodisinfection therapy (aPDT) with standard of care for prevention of surgical site infections in patients undergoing major…
- Conditions
- Surgical Site Infections, Infections, Surgical Wound Infections, Anti-Infective Agents
- Trial name
- LANTERN (NCT07189858)
- Testing
- Nasal antimicrobial photodisinfection therapy
- Where
- 4 sites in Canada
- Volunteers
- 401 people
- Sponsor
- Ondine Biomedical Inc.
Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection, Staphylococcus Aureus Infection, Acinetobacter Infection
- Trial name
- REVERSE (NCT04803708)
- Testing
- TP-102
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Technophage, SA
Staphylococcal Infections
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main objective of this study will be to test the safety and behavior of Altastaph in patients with S.aureus bacteremia and continuing fever
- Trial name
- NCT00063089
- Testing
- S. aureus Immune Globulin Intravenous (Human) 5%
- Volunteers
- 40 people
- Sponsor
- Nabi Biopharmaceuticals
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.